Improving targeted therapies for osteoporosis
Official title: Optimizing bone surface targeting of therapeutic antibodies for osteoporosis
Funded at University of Michigan at Ann Arbor · NIH-11029485 · Data updated 2026-11-12
This study is looking at new ways to make osteoporosis treatments work better by delivering special antibodies right to the bones, which could help patients get safer and more effective care with fewer doses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | May 6, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $465,663 |
| NIH project number | 1R01AR085170-01 |
| Project ID | NIH-11029485 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with osteoporosis who may benefit from improved therapeutic options.
✕Less likely to help
Patients who are not diagnosed with osteoporosis or those who have contraindications to antibody therapies may not receive benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of osteoporosis treatments by developing methods to deliver therapeutic antibodies directly to bone surfaces. By increasing the local concentration of these therapies, the research aims to improve their safety and efficacy while reducing the frequency and dosage required for administration. The approach involves optimizing the pharmacokinetics and pharmacodynamics of a specific antibody in both healthy and osteoporotic animal models, with the goal of translating these findings into better treatment options for patients.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective osteoporosis treatments that require less frequent dosing.
How similar studies have gone: Previous research has shown promise in enhancing the delivery of therapeutic antibodies, suggesting that this approach could lead to significant advancements in osteoporosis treatment.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Greineder, Colin Fred — University of Michigan at Ann Arbor
- Study coordinator: Greineder, Colin Fred
Related research
Other NIH-funded projects on the same topics.
-
Or olive-oil derived compound to prevent bone loss in women
A safe, orally taken nutraceutical may help prevent osteoporosis in adult women by supporting bone formation and reducing bone loss.
-
When to stop, switch, or pause long-term osteoporosis medicines for older adults
This project looks at whether stopping, switching, or taking breaks from long-term osteoporosis drugs changes fracture risk and side effects for older adults.
-
Cortical Bone Mechanics Technology to better screen for osteoporosis
A new noninvasive test called CBMT uses ulnar flexural rigidity to predict fracture risk better than standard bone density tests, helping adults who may be at risk for osteoporosis.
-
Gene therapy for osteoporosis linked to ALDH2 deficiency in postmenopausal East Asian women
A gene therapy approach is being developed to reduce osteoporosis risk in postmenopausal East Asian women who have ALDH2 deficiency and drink alcohol.
-
Metabolomics clues to osteoporosis risk in diverse populations
A study using small molecules in blood samples to understand osteoporosis risk, with a focus on aging, ethnicity, and sex differences.
-
Single-Cell Study of Bone Cells to Understand Osteoporosis
Researchers will study individual bone-related cells from people to uncover why aging leads to weaker bones and higher fracture risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.